A key step towards setting a benchmark for tackling transplant‐associated thrombotic microangiopathy.

A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathy Improvements in allogeneic haematopoietic cell transplantation (allo-HCT) techniques and supportive care strategies over the last several decades have resulted in a marked reduction in non-relapse mortality (NRM) due to fewer serious complications. This is especially relevant given the advent of novel complement pathway inhibitors and agents aimed at restoring endothelial integrity (Sicre De Fontbrune I et al. i , [31]; De Fontbrune I et al. i , [9]; Yeates I et al. i , [33]; Khaled I et al. i , [18]). Among the 23 665 paediatric and adult and allo-HCT recipients, they found 661 cases of TA-TMA resulting in a 3-year cumulative incidence estimate of 3%, which is considerably lower than what has been reported in recent studies (Jodele I et al. i , [16]; Dvorak I et al. i , [11]). [Extracted from the article]